AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02189759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Kangaroo Mother Care to one hour after birth
Description: Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
Study NCT03403361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens Somatom Definition Edge
Description: In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
Study NCT03403361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Brilliance Big Bore CT/simulator
Description: In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
Study NCT02604654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqitongluo granule
Description: administered after dissolved
Study NCT00107315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00107315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00527683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin
Description: crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
Study NCT00527683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orange juice is administered twice daily in containers indistinguishable from the treatment arm.
Study NCT00527683 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group therapy
Description: Participants attend group sessions once a week
Study NCT00527683 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group therapy
Description: Participants attend group sessions once a week
Study NCT01761591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with Svelte Acrobat
Description: Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
Study NCT01761591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with other BMS
Description: Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
Study NCT02890953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumostem
Description: direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
Study NCT02890953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: direct intracerebroventricular injection of normal saline via ventricular tap
Study NCT03822455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OligoG DPI
Description: OligoG Dry Powder for Inhalation
Study NCT03822455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OligoG DPI
Description: OligoG Dry Powder for Inhalation
Study NCT03061721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 1 mg
Description: Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
Study NCT03061721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 2 mg
Description: Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
Study NCT03061721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 4 mg
Description: Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
Study NCT03061721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
Study NCT04489147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 850 mg orally twice daily along the cycle of ICSI
Study NCT01431014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasonelow-dose
Description: 5mg
Study NCT02189759 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Kangaroo Mother Care to one hour after birth
Description: Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
Study NCT02189759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Kangaroo Mother Care to discharge
Description: Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
Study NCT01431014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasonehigh-dose
Description: 15 mg
Study NCT01129713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretol
Description: Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
Study NCT01129713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
Study NCT00518648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention program
Description: Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
Study NCT00518648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study NCT00642434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol
Description: variable
Study NCT00642434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: variable
Study NCT03315897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: 40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.
Study NCT03315897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
Study NCT01703208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
Study NCT01703208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to omarigliptin capsule or tablet administered orally once weekly
Study NCT02060630 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open surgical revascularization
Study NCT02060630 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular revascularization
Description: A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
Study NCT03898466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Inhaled corticosteroid
Study NCT03898466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Placebo inhaler
Study NCT03213782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature based sounds
Description: Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
Study NCT00096226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Carboplatin
Study NCT00096226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Paclitaxel
Study NCT00096226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Study NCT00096226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Carboplatin
Study NCT00096226 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT00096226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Paclitaxel
Study NCT01880749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study NCT04816136 — intervention group
Intervention type: OTHER
Intervention: Sleep recording (already done)
Description: Sleep recording (already done)
Study NCT04585230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: CBD oil Roll-On Stick
Study NCT04585230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Oil
Description: Mineral Oil- Roll on Stick
Study NCT04585230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Roll- On stick with no CBD and no Mineral Oil
Study NCT03207737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MENTOR + Telehealth
Description: Participants will live on campus for one week and complete the MENTOR program, which is a course about resilience and how nutrition, exercise and mindfulness help with resilience for individuals with a spinal cord injury. Different experts will cover the three main topics with lectures and application of knowledge through related activities. Participants will then begin a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
Study NCT03207737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth Only
Description: Participants will complete a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
Study NCT03387007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support training for school teachers
Description: The intervention for this study was schoolteachers' training on psychosocial support.A clinical psychologist provided 2-day training (a total of 16 hours) training on psychosocial support for the schoolteachers
Study NCT00349921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
Study NCT00349921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine
Description: Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
Study NCT00349921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive substance
Study NCT04171791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199 (venetoclax)
Description: Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
Study NCT02493257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Study NCT02493257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01183052 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training
Description: 20 sessions of training
Study NCT04161443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: * Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~* The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention).
Study NCT04161443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: * Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~* The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention).
Study NCT00809991 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionation
Description: 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). T
Study NCT01168791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin in combination with palifosfamide-tris
Description: palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles.
Study NCT01168791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin in combination with placebo
Description: doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles.
Study NCT02042053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Study NCT02042053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Study NCT00041483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anecortave Acetate 15 mg sterile suspension
Study NCT00041483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy (PDT)
Study NCT02189759 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Kangaroo Mother Care to discharge
Description: Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
Study NCT03632876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: retinyl palmitate
Description: The intervention is a daily vitamin A supplement.
Study NCT03488043 — intervention group
Intervention type: PROCEDURE
Intervention: Needle lung biopsy
Description: Needle lung biopsy
Study NCT04696900 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise training
Description: exercise training in an approved rehabilitation program
Study NCT05554549 — intervention group
Intervention type: OTHER
Intervention: Dietary pattern observed
Description: Dietary pattern: regular meat-eater, occasional meat-eater, pescatarian, and vegetarian. There are no interventions in this observational cohort.
Study NCT04205799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
Study NCT01991275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The intravenous patient-controlled analgesia
Description: The intravenous injection of morphine using the patient-controlled analgesia machine
Study NCT01991275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The intravenous patient-controlled analgesia
Description: The intravenous injection of morphine using the patient-controlled analgesia machine
Study NCT01991275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The intrathecal morphine injection
Description: A single injection of morphine intrathecally
Study NCT02457806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: Active Spray with deliverable volume of 0.1 mL
Study NCT02457806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: Active Spray with deliverable volume of 0.1 mL
Study NCT02457806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo spray
Description: Aqueous solution to deliver 0.1 mL per unit
Study NCT02457806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: Aqueous solution to deliver 0.1 mL per unit
Study NCT03194568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Vertebral Tether
Description: Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
Study NCT02056314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic tutorial
Description: The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
Study NCT00219466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Oxide Diaper Rash Ointment
Description: Desitin Original at diaper change
Study NCT00219466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aloe Vera/Tocopherol/Zinc Oxide Cream
Description: Desitin Creamy at diaper change
Study NCT04000399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRITEPath
Description: BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
Study NCT03473041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid sling
Description: sling formed of surgeon tailored autologous rectus sheath and polypropylene arms
Study NCT03473041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O
Description: midurethral transobturator vaginal tape
Study NCT04074252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lofstrand Crutches
Description: Device: Set of Lofstrand Crutches
Study NCT04074252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Crutches
Description: Device: Set of Axillary Crutches
Study NCT01662505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Patient to receive volasertib
Study NCT04458792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraffin tissue samples
Description: Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue